Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 6, 1996 - Issue 8
Submit an article Journal homepage
6
Views
5
CrossRef citations to date
0
Altmetric
Research

Section Review Anti-infectives: Developments in viral hepatitis during 1995

Martin J Slater Glaxo Wellcome Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts, SG1 2NY, UK
&
Berwyn E Clarke Glaxo Wellcome Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts, SG1 2NY, UK
Pages 739-746 | Published online: 29 Feb 2008

References to Primary Literature

  • DEINHARDT F, HOLMES AW, CAPPS RI3, POPPER H: Stud-ies on the transmission of disease of human viral hepatitis to marmoset monkeys J. Exp. Med. (1967) 125:673–687.
  • KARYANNIS P, PETROVIC LM, FRY M et al.: Studies of GB hepatitis agent in tamarins. Hepatology (1989) 9:186–192
  • TABOR E, SEEF LB, GERETY RJ: Lack of susceptibility of marmosets to human non-A, non-B hepatitis. J. Infect. Dis. (1979) 140:794–797.
  • PURCELL RH: The discovery of the hepatitis viruses. Gastroenterology (1993) 104:955–963.
  • SIMONS JN, PILOT-MATIAS TJ, LEARY TP et al.: Identifica-tion of two flavivirus-like genomes in the GB hepatitis agent. Proc. Natl. Acad, Sci. USA (1995) 92:3401–3405.
  • MEURHOFF AS, LEARY TP, SIMONS JN et al.: Genomic organisation of GB viruses A and B: Two new members of the Flaviviridae associated with GB agent hepatitis. J. Vivo!. (1995) 69:5621–5630.
  • SCHLAUDER GG, DAWSON GJ, SIMONS JN et at: Molecular and serological analysis in the transmission of the GB hepatitis agents. J. Med. Vila (1995) 46:81–90.
  • SIMONS JN, LEARY TP, DAWSON GJ et al.: Isolation of novel virus-like sequences associated with human hepatitis. Nature Medicine (1995) 1:564–569,
  • LEARY TP, SCOTT MUERHOFF AS, SIMONS JN et al.: Se-quence and genomic organisation of GBV-C: a novel member of the Flaviviridae associated with human non-A-E hepatitis J. Med Virot (1996) 48:60–67.
  • LEARY TP, MUERHOFF AS, SIMONS JN et al.: Consensus oligonucleotide primers for the detection of GB virus C In human cryptogenic hepatitis. J. Vim!. Methods (1996) 56:119–121.
  • PILOT-MATIAS TJ, MUERHOFF AS, SIMONS JN etal.: Iden-tification of antigenic regions in the GB hepatitis viruses GBV-A, GBV-B and GBV-C. J. Med Virol. (1996) 48:4.
  • ZUCKERMAN AJ: The new GB hepatitis viruses. Lancet (1995) 345:1453–1454.
  • YOSHIBA M, OKAMOTO H, MISHIRO S: Detection of the GBV-C hepatitis virus in serum from patients with f-ulminant hepatitis of unknown origin. Lancet (1995) 346:1131–1132.
  • LINNEN J, WAGES J, ZHANG-KECK ZY at al.: Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissable agent. Science (1996) 271:505–508.
  • ALTER HJ, PURCELL RH, SHIH JW at al.: Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with an acute chronic non-A, non-B hepatitis. New Engl. J. Med. (1989) 321:1494–1500.
  • GERBER MA: Relation of hepatitis C virus to hepatocel-lular carcinoma. J. Hepatol. (1993) 17\(Suppl. 3):108–111.
  • TINE F, MAGRIN S, CRAM A, PAGLIARO L: Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. J Hepatol. (1991) 13:192–199.
  • DAVIS GL, BALART LA, SCHIFF ER et al.: Treatment of chronic hepatitis C with recombinant interferon alpha. A multicentre randomized controlled triaL New Engl. J. Med. (1989) 321:1501–1506.
  • CAUSSE X, GODINOT H, CHEVALLIER M et al.: Compari- son of 1 or 3 MU of interferon a-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroen-terology (1991) 101:497–502.
  • MARCELLIN P, BOYER N, G1OSTRA E etal.: Recombinant human a-interferon in patients with chronic non-A, non-B hepatitis: a multicentre randomized controlled trial from France. Hepatology (1991) 13:393–397.
  • SARACCO G, ROSINA F, CERENZIA MRT et al.: A random-ized controlled trial of interferon a-2b as therapy for chronic non-A, non-B hepatitis. J. Hepatot (1990) 11:543–349.
  • TREPO C, HABERSETZER F, BAILLY F et al.: Interferon therapy for hepatitis C. Antiviral Research (1994) 24 : 155–163.
  • ALBERTI A, CHEMELLO L, BONETTI P, C et al.: Treatment with interferon(s) of community acquired chronic hepatitis and cirrhosis type CJ Hepatol. (1993) 17\(Suppl. 3):S123–S126.
  • POYNARD T, BEDOSSA P, MATHURIN P etal.: Efficacy of long term recombinant interferon-a in patients with chronic hepatitis C. A randomized clinical triaL Gas-troenterot Clin. Biol. (1991) 15:615–619.
  • HAGIWARA H, HAYASHI N, MITA E at al.. Quantitativeanalysis of hepatitis C virus RNA in serum during Interferon alfa therapy. Gastroenterology (1993) 104:877–883.
  • LAU JYN, DAVIS GL, KNIFFEN J: Significance of serumhepatitis C virus RNA levels in chronic hepatitis C. Lancet (1993) 341:1501–1504.
  • AIYAMA T, YOSHIOKA K, HIROFUJI H etal,: Changes in serum hepatitis C virus RNA titre and response to Interferon therapy in patients with chronis hepatitis C. Dig Dis Sci. (1994) 39:2244–2249.
  • JENKINS PJ, CROMIE SL, BOWDEN DS, FINCH CF, DUDLEY FJ: Chronic hepatitis C and interferon alpha therapy - predictors of long tetra response. Med J. Aust. (1996) 164:150–152.
  • SHERLOCK S: Antiviral therapy for chronic hepatitis C Infection J. Hepatol. (1995) 23(S2):3–7.
  • MARTIN-PEIGNOUX M, MARCELLIN P, POUTEAU M et al : Pretreatment serum hepatitis virus RNA levels and hepatitis C virus genotype are the main and inde-pendent prognostic factors of sustained response to Interferon alfa therapy in chronic hepatitis C. Hepatol-ogy (1995) 22:1050–1056.
  • ENOMOTO N, SAKUMA I, ASAAHINA Y etal,: Comparison of full length sequences of interferon-alpha sensitive and resistant hepatitis C virus lb. Sensitivity to inter-feron is conferred by amino add substitutions in the NS5A region. J. Clin. Invest. (1995) 96:224–230.
  • KASAHARA A, HAYASHI N, HIRAMATSU N etal.: Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology (1995) 21:291–297.
  • BRESCI G, PARISI G, BANTI S et al.: Chronic hepatitis C - what treatment for non-responders to recombinant Interferon-alpha Clin. Drug Invest. (1996) 11:224–228.
  • BONKOVSKY HL, CLIFFORD BD, SMITH LJ, ALLAN C, BANNER B: High-dose interferon-a 2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C. A controlled randomized triaL Dig. Dis. Sci. (1996) 41:149–154.
  • BRESCI G, PARISI G, BANTI S, BERTONI M, CAPRIA A:Treatment of relapses in patients with chronic hepati-tis C with recombinant a-interferon. Clin. Drug Invest. (1995) 10:215–220.
  • IINO S, HINO K, YASUDA K Current state of interferontherapy for chronic hepatitis C. Intervirology (1994) 37:87–100.
  • RENAULT PF, HOOFNAGLE JH: Side-effects of alpha in-terferon. Semin. Liver Dis. (1989) 9:273–277
  • KAWANO T, SHIGEHIRA M, UTO H at al.: Retinal compli-cations during interferon therapy for chronic hepatitis C. Am. J. Gastroenterol. (1996) 91:309–313.
  • RASI G: New combination drug therapy for chronic hepatitis C doubles sustained remission over those rates reported with standard therapy Dig. Dis. Week, San Mateo, California, (1996).
  • REICHARD 0, ANDERSSON J, SCHVARCZ R, WEILAND 0: Ribavirin treatment for chronic hepatitis C. Lancet (1991) 337:1058–1061.
  • DUSHEIKO G, WEILAND 0, THOMAS H etal,: Results of a placebo-controlled study of ribavirin in patients with chronic hepatitis C. Hepatology (1994) 20:206A,
  • BODENHEIMER HC, LINDSAY RE, DAVIS GL, LEWIS JH: Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology (1994) 20:(4:2)207A Abstract 441.
  • DI BISCEGL1E AM, FRIED MW, SWAIN MG etal: Random-ized, double-blind placebo-controlled trial of ribavirin therapy for chronic hepatitis C. Hepatology (1993) 18:(4:2)93A Abstract 145.
  • REICHARD 0, YUN Z-B, SONNERBERG A, WEILAND 0: Hepatitis C viral RNA titres in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. J Med. Vim!. (1993) 41:99–102.
  • KOSKINAS J, IIBBS C, SALEH MG etal.: Effects of ribavirin on intrahepatic and extrahepatic expression of hepati-tis C virus in interferon nonresponsive patients. J. Med Vim!. (1995) 45:29–34.
  • GANE EJ, TIBBS CJ, RA.MAGE JK, PORTMANN BC, WILLIAMS R: Ribavirin therapy for hepatitis C infection following liver transplantation. Transplant. Int. (1995) 8:61–64.
  • DI-BISCEGLIE AM, CONJEEVARAM HS, FRIED MW at aL: Ribavirin as therapy for chronic hepatitis CA random-ized, double-blind, placebo-controlled triaL Ann. Intern. Med. (1995) 123:897–903.
  • BRILLANTI S, GARSON J, FOLI M at al.: A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gas-troenterology (1994) 107:812–817.
  • CHEMELLO L, CAVALLETTO L, BERNARDINELLO E et al.: Response to ribavirin, to interferon and to a combina-tion of both in patients with chronic hepatitis C and its relation to HCV genotypes. J. Ilepatol. (1994) 21:(Suppl. 1):S12.
  • LAI MY, YANG PM, KAO J1-1 at al.: Combination therapyof a-interferon and ribavirin in patients with chronic hepatitis C: an interim report. Hepatology (1993) 18:(4:2):93A Abstract 146.
  • CHEMELLO L, CAVALLE'rTO L, BERNARDINELLO E et al:The effect of interferon alpha and ribavirin combina-tion therapy in naive patients with chronic hepatitis C. I. Hepatol. (1995) 23:(Suppl. 2):8–12.
  • BRILLANTI S, MIGLIOLI M, BARBARA L: Combination antiviral therapy with ribavirin and interferon alpha in interferon alpha relapsers and non-responders: Italian experience. J. Hepatol. (1995) 23:(Suppl. 2)13–16.
  • BRACONIER JH, PAULSEN 0, ENGMAN K, WIDELL A: Combined alpha-interferon and ribavirin treatment in chronic hepatitis C: a pilot study. Scand. J. Infect. Dis. (1995) 27:325–329.
  • SCHVARCZ R, ANDO Y, SOENNERBORG A, WEILAND 0:Combination treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alpha alone: Swedish experience. J. Hepatol. (1995) 23\(Suppl. 2):17–21.
  • BIZOLLON T, DUCERF C, TREPO C: New approaches tothe treatment of hepatitis C virus infection after liver transplantation using ribavirin J. Hepatology (1995) 23:22–2
  • CLARICE BE: Approaches to the development of novelInhibitors of hepatitis C virus replication. J. Viral Hepa-titis (1995) 2:1–8.
  • MORI A, YAMADA K, KIMURA J et al.: Enzymatic charac-terization of purified NS3 serine proteinase of hepatitis C virus expressed in Escbericbia coil. FEBS Lenets (1996) 378:37–42.
  • HAHM B, HAN DS, SUNG H et al.: NS3-4A of hepatitis C virus is a chymotrypsin-like protease. J. Virol. (1995) 69:2534–2539.
  • BOUFFARD P, BARTENSCHIAGER R, AHLBORN-LAAICE L et al.: An in vitro assay for hepatitis C NS3 serine proteinase. Virology (1995) 209:52–59.
  • SHOJI I, SUZUKI T, CH1EDA S et al.: Proteolytic activity of NS3 serine proteinase of hepatitis C virus efficiently expressed inEscbericbia coll. Hepatology (1995) 22:1648–1655.
  • BARTENSHLAGER R, AHLBORN-LAAKE L, MOUS J, JACOB-SEN H: Kinetic and structural analysis of hepatitis C virus poly-protein processing J. Vtrol. (1994) 67:3835–3844.
  • FAILLA C, TOMEI L, DE FRANCESCO R: Both NS3 andNS4A are required for processing of hepatitis C virus polyprotein. J. Virol, (1994) 67:4017–4026.
  • UN C, PRAGAI B, GRAKOUI A, XU J, RICE C: The hepatitis C virus NS3 serine protease: trans processing require-ments and cleavage kinetics. J. Virol (1994) 68:8147–8157.
  • TANJ1 Y, HIJI1CATA M, SATOH S, KANEKO T, SHIMOTO-HNO K: Hepatitis C virus-encoded- nonstructural pro-tein NS4A has versatile function in viral protein processing. J. Virol. (1995) 69:1575–1581.
  • BARTENSCHLAGER R, VOLKER L, WILKINSON T, KOCH JO:Complex formation between the NS3 serine-type pro-teinase of the hepatitis C virus and NS4A and its impor-tance for polyprotein maturation. J. Virol. (1995) 69:7519–7528.
  • UN C, THOMSON JA, RICE CM: A central region in the hepatitis C virus NS4A protein allows formation of an active NS3-NS4A serine proteinase complex in vivo and in vitro. J. Virol. (1995) 69:4373–4380.
  • TOMEI L, FAILLA C, VITALE RL, BIANCHI E, DE FRANCESCO R: A central hydrophobic domain of the hepatitis C virus NS4A protein is necessary and sufficient for the activa-tion of the NS3 protease. J. Gen. Virol. (1995) 77:1065–1070.
  • SATOH S, TANJI Y, HIJIICATA M, KIMURA K, SHIMITOHNO K: The N-terminal region of hepatitis C virus nonstruc-tural protein 3 (NS3) is essential for stable complex formation with NS4A. j Virol (1995) 69:4255–4260.
  • SUZICH JA, TAMURA JK, PALMER-HILL F et al.: Hepatitis C virus NS3 protein polynucleotide-stimulated nucleo-side triphosphatase and comparison with the related pestivirus and flavivirus enzymes. J. Virol. (1993) 67:6152–6158.
  • WARRENER P, TAMURA JK, COLLETT MS: RNA-stimulated NTPase activity associated with yellow fever virus NS3 protein expressed in bacteria. JVirol. (1993) 67:989–996.
  • GWACK Y, KIM DW, HAN J11, CHOE J: NTPase activity of hepatitis C virus NS3 protein expressed in insect cells. Molecules Cells (1995) 5:171–175.
  • KANAI A, TANAB, K AND KOHARA M: Poly(U) bindingactivity of hepatitis C virus NS3 protein, a putative RNA helicase. FESS Lett. (1995) 37:221–224.
  • KIM OW, GWACK Y, HAN JH, CHOE J: C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity. BBRC (1995) 215:160–166.
  • LING J, PETERSON DL: Expression, isolation and charac-terization of the hepatitis C virus ATPase/RNA helicase. Arch. Biochem. Biophys. (1995) 323:47–53.

References to Patent Literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.